MARKET

DGNOF

DGNOF

Diagnos Inc
OTCMQB
0.178
-0.009
-4.87%
Opening 10:47 04/16 EDT
OPEN
0.180
PREV CLOSE
0.187
HIGH
0.182
LOW
0.178
VOLUME
44.50K
TURNOVER
7.97K
52 WEEK HIGH
0.288
52 WEEK LOW
0.134
MARKET CAP
21.42M
P/E (TTM)
-5.4238
1D
5D
1M
3M
1Y
5Y
1D
Diagnos targets Health Canada submission for new CARA in May, FDA filing by Q3-end
Reuters · 04/08 16:20
DIAGNOS INC - REMAINS ENGAGED IN SAUDI FOOD AND DRUG AUTHORITY REVIEW PROCESS FOR CARA
Reuters · 04/08 16:14
Diagnos completes annual US FDA medical device facility registration renewal
Reuters · 04/01 16:02
Diagnos extends expiry of 5.23 million warrants to Sept. 25, 2026
Reuters · 04/01 15:50
DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration
Barchart · 04/01 10:50
Diagnos Extends Expiry of 8,333,333 Stock Warrants to Sept. 5, 2026
Reuters · 03/05 21:06
Diagnos Extends Convertible Debenture Maturity to March 2027 and Cuts Conversion Price to $0.32
Reuters · 03/05 20:45
DIAGNOS ANNOUNCES AMENDMENTS TO CONVERTIBLE DEBENTURES AND STOCK WARRANTS
Reuters · 03/05 20:45
More
About DGNOF
Diagnos Inc. is a Canadian company, which is engaged in the early detection of critical eye-related health problems using advanced technology based on Artificial Intelligence (AI). It markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.

Webull offers Diagnos Inc stock information, including OTCMQB: DGNOF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DGNOF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DGNOF stock methods without spending real money on the virtual paper trading platform.